23:29 , Jun 11, 2019 |  BC Extra  |  Company News

Management Tracks: Agios’ Biller to retire as CSO; plus Vectura, Molecular Partners, F-star and more

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said CSO Scott Biller will retire at year end. The cellular metabolism company is searching for a successor. Vectura Group plc (LSE:VEC) said CFO Paul Fry will serve as interim CEO...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
20:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Vectura discontinues asthma therapy after Phase III miss

Vectura Group plc (LSE:VEC) said it will discontinue development of VR475 after both doses of the compound missed the primary endpoint in a Phase III trial to treat severe uncontrolled asthma. Both twice-daily 0.5 and...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
22:34 , Sep 4, 2018 |  BC Extra  |  Financial News

Another C-suite departure at Immunocore

Chief Strategy and Business Officer Kevin Pojasek has left Immunocore Ltd. (Abingdon, U.K.) to join SV Health Investors as venture partner. Pojasek is the fifth C-level executive to leave the TCR company since former CEO...
21:09 , Jul 16, 2018 |  BC Extra  |  Company News

Management tracks: Cerecor, Sangamo

Neurology play Cerecor Inc. (NASDAQ:CERC) said CFO Mariam Morris is stepping down. She is succeeded by Joe Miller, who was VP of finance at Sucampo Pharmaceuticals Inc., which Mallinckrodt plc (NYSE:MNK) acquired. Additionally, Cerecor hired...
19:58 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Mylan expecting another delay for generic Advair

Mylan N.V. (NASDAQ:MYL) said it expects to receive a second complete response letter from FDA for an ANDA of a generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK). Any delay would be a...
19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
22:40 , Jun 14, 2018 |  BC Extra  |  Company News

Mylan expecting another delay for generic Advair

Mylan N.V. (NASDAQ:MYL) said it expects to receive a second complete response letter from FDA for an ANDA of a generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK). Any delay would be a...
13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...